ESMO: Relay’s RLY-4008 Shows High Response, Lower Toxicity In Cholangiocarcinoma
Executive Summary
The new data bolster the company’s hypothesis that more specific targeting of FGFR2 can overcome the toxicity limitations of other FGFR inhibitors.
You may also be interested in...
Relay Therapeutics Hopes ‘Safety First’ Approach Will Pay Off For Targeted Breast Cancer Drug
Investors have deserted Relay after RLY-2608 failed to produce any clear response in breast cancer patients, but it maintains underlying data represent proof-of-concept for a more targeted and less toxic competitor to Novartis's Piqray.
Taiho’s Lytgobi Faces Heavy Competition, But Sets Efficacy Bar For Now
The FGFR inhibitor beats prior entrants on efficacy in cholangiocarcinoma, although Relay presented data at ESMO for its investigational RLY-4008 showing especially high efficacy and tolerability.
Finance Watch: Third Harmonic Launches The Largest IPO In Months
Biopharma stock prices overall are trending down again, but standout firms are raising cash, including the first company to price an IPO over $100m since May, Third Harmonic. Also, Sarepta and Alnylam launched large note offerings, totaling $1bn and $900m, respectively.